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Objective: To evaluate the effect of implementation of a human immunodeﬁciency virus (HIV) educational
intervention on universal screening for HIV in a prenatal clinic setting.
Methods: In this retrospective cohort study, frequencies of offering and acceptance of HIV testing were
compared before and after an educational intervention performed by an HIV-focused nurse. The records of 293
women seeking prenatal care before the intervention and 206 women seeking prenatal care after the
intervention were reviewed for offering and acceptance of HIV testing. Fisher’s exact test and logistic regression
were used to evaluate the relationship between the educational intervention and the offering and acceptance of
HIV testing.
Results: The frequency of HIV test offering at ﬁrst visit and test acceptance before the educational intervention
were 96.5% and 74.8%, respectively, and after the intervention were 99.5% and 84.3%, respectively. This
improvement in offering (3% change) and acceptance (9.5% change) was statistically signiﬁcant (offering at ﬁrst
visit: OR=7.27, 95% CI=1.02 to 316.9; test acceptance: OR=1.82, 95% CI=1.14 to 2.88). Test acceptance
was statistically signiﬁcantly improved in the post-intervention group after controlling for confounding variables
(OR=2.02, 95% CI=1.2 to 3.39).
Conclusion: The addition of an HIV-focused nurse to a clinic setting improved the frequency of test offering at
ﬁrst visit and of acceptance of HIV testing by pregnant women.
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INTRODUCTION
Mother-to-child transmission is the dominant
mode of acquisition of HIV among young
children worldwide
1. In the USA signiﬁcant
progress has been made in preventing transmis-
sion, with fewer than 200 new cases of infant
infection reported in 1999
1. This was unthinkable
just 10 years ago. In 1994, the US Public Health
Service recommended the use of zidovudine
(ZDV) during pregnancy to prevent the perinatal
transmission of HIV infection
2,3. The Pediatric
Acquired Immune Deﬁciency Syndrome Clinical
Trials Group Protocol 076 Study Group
(PACTG) showed in 1994 that providing preg-
nant women with ZDV reduced perinatal
transmission of HIV from 25.5% to 8.3%
4,5.
Other retrospective data have supported this
ﬁnding
6. Data from the PACTG trial proved that
ZDV reduced transmission regardless of viral
load
7. The American College of Obstetricians and
Gynecologists and the American Academy of
Pediatrics both support a recommendation made
by the Institute of Medicine to include a national
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routine part of prenatal care
2,8.
Despite the extremely encouraging evidence
showing decreased transmission with ZDV treat-
ment in pregnant women, screening for HIV in
this population remains inadequate. Women who
obtain prenatal care still complete their pregnan-
cies without being screened. Suggestions in the
literature for universal screening of all pregnant
women began as early as 1991
9. Before that time,
the recommendations had been to screen only
patients with risk factors
9. Many reasons have
been cited for the lack of universal screening,
including limitations of provider time, lack of up-
to-date education, and inequity of care
10,11. Both
prospective and retrospective studies have shown
improvements in the rates of testing with
protocols for universal testing
2,12,13,14. The future
holds a multitude of possibilities for improving
screening. State legislation is one area in which
improvements have already been made. When
the state of Connecticut instituted mandatory
HIV screening for all neonates if antepartum
testing had not been done, the frequency of
testing increased from 39.1% to 91.4%
15. Other
methods include standard protocols being created
in prenatal care ofﬁces, updates in education to
those providing prenatal care, and positioning of
staff reminders such as posters in ofﬁces.
The purpose of this investigation was to
evaluate the improvement in test offering and
test acceptance achieved after the Magee-Wo-
mens Ambulatory Clinic added an HIV-focused
educational nurse to their staff.
METHODS
In this investigation, a cohort of women was
studied after an intervention to educate prenatal
care providers, and was compared with a pre-
intervention historical control. The cohort com-
prised women receiving prenatal care in the
Women’s Ambulatory Clinic at Magee-Womens
Hospital before and after the addition of an HIV-
focused nurse and education program (Table 1).
The Ambulatory Care Clinic is a site of care for a
population of predominantly low socio-economic
status.
There are seven separate clinics, including a
clinic run by a certiﬁed nurse midwife, a teen
clinic run by a nurse practitioner, and a clinic for
medical complications of pregnancy run by a
senior resident physician. All the clinics were
included in this evaluation and all have direct
supervision by an attending physician. The
intervention involved a brief standardized educa-
tional program provided by the intervention
nurse and focused on the importance of universal
screening for HIV as well as non-confrontational
methods of patient education and counseling,
with the goal of improving acceptance rates of
testing in the clinic.
This initial program was followed by the
continued presence of the nurse in the clinics
and her availability for coordinating medical and
social care of any HIV-positive clients in the
clinics and also of their infants immediately after
birth. At any one time, there were approximately
5 pregnant women with HIV infection within the
clinic system.
After Institutional Review Board approval, the
subjects were identiﬁed using medical records
charts located in the Ambulatory Clinic. A
database search was performed to identify all of
the new clients between September and Novem-
ber 2001, i.e. during the 3 months before the
interventional nurse was hired. These women
comprised the pre-intervention group. The
database was again searched 6 months after the
nurse’s interventions had begun, to identify all
Table 1 Key elements of staff education regarding
intervention
Staff Element





Provider awareness of refusal
{Resident physicians Beneﬁts of testing
and midwives Pre- and post-test counseling
Risk factors
Counseling post-refusal
*Three sessions; {two sessions.
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These women comprised the post-intervention
group. The medical records were screened retro-
spectively by a single investigator (B.L.A.). The
outcomes of interest were the proportion of
patients offered testing and the proportion of
patients consenting to testing. We evaluated
documentation of test offering, acceptance or
decline, reason for decline, self-reported risk
factors and test completion.
Continuous variables were assessed for normal-
ity using the Kolmogorov-Smirnov test, through
graphical evaluation, and by evaluating compar-
ability of mean and median. Categorical variables
were compared using Fisher’s exact test. Uni-
variate odds ratios were determined using logistic
regression.
Individual candidate confounders and effect
modiﬁers were tested for association with both
exposure (intervention) and outcome (accep-
tance). Variables that demonstrated a univariate
relationship (p50.1) with either exposure, out-
come, or both, were considered. Forward-
stepping multivariable logistic regression was used
to generate adjusted odds ratios in consideration
of possible confounders. Except as noted above,
p50.05 was considered statistically signiﬁcant.
Analyses were performed using Stata 7.0 for
Windows (Stata, College Station, TX, USA).
RESULTS
Patient demographics were relatively similar
between the groups (Table 2). There were more
African American women in the pre-intervention
group. The prevalence of several risk factors was
tracked, including history of intravenous drug use
or sex with someone usng intravenous drugs; sex
with more than ﬁve partners in 1 year; sex with a
male who had been in jail; sex with a male who
had sex with other males; blood transfusion; travel
to an endemic area; sexual assault; sex with a
known HIV-positive male; and a personal history
of a sexually transmitted disease.
Sexually transmitted diseases screened in the
subject’s history included gonorrhea, chlamydia,
trichomonas, herpes and pelvic inﬂammatory
disease. The groups were very similar, but differed
in several factors: a history of sex with more than
ﬁve partners in 1 year (p=0.004), a history of
Chlamydia trachomatis infection (p=0.005), and a
history of herpes simplex virus infection
(p50.001) were all more common in the pre-
intervention group (Table 3). Test acceptance
improved from 74% to 84% after the intervention
(p=0.011, OR=1.82, 95% CI=1.14 to 2.88).
The adjusted odds ratio for test acceptance was
2.02 (95% CI=1.2 to 3.4). This odds ratio was
obtained after controlling for a history of sex with
more than ﬁve partners in 1 year, of a psychiatric
disorder requiring medication, of herpes or any
sexually transmitted disease, of sex with a man
who had been in jail and of alcohol abuse.
Test offering at ﬁrst visit improved from
96.58% to 99.51% with intervention. The
unadjusted odds ratio for test offering at ﬁrst visit
was 7.27 (95%CI=1.02 to 316.9). No subjects
were found to be infected with HIV.
We also evaluated the reason for decline of
testing in order to direct future counseling efforts.
Most commonly, there was no reason given in the
charts for the client’s decision to decline testing. In
the charts that did state a reason for refusal, a
‘‘recent test’’ was the most frequently cited
explanation. The pre-intervention group was
more likely to give no reason for refusal, whereas
the post-intervention group was more likely to
cite a recent test as the reason for decline (Table 4).
Table 2 Patient Demographics
Characteristic Pre-intervention Post-intervention p Value
*Median age in years (range) 22 (10–44) 22 (14–39) 0.20
{% African American 55.8% 40.6% 0.02
*Median gravidity (range) 2 (1–17) 2 (1–9) 0.72
*Median parity (range) 1 (0–12) 1 (0–6) 0.85
* Mann-Whitney U test for comparisons of medians
{Fisher’s exact test for comparison of frequency.
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Our data demonstrate that improvement in
universal HIV screening of women attending
prenatal clinics can be achieved with the addition
of an HIV-focused nurse educator. Training
aimed at prenatal care providers improved both
test offering at ﬁrst visit and acceptance of HIV
testing. Most importantly, our data revealed an
improvement in test acceptance from 74% to 84%
after the intervention, with an adjusted odds ratio
of 2.02 (95% CI=1.2 to 3.4). It is the ultimate
goal of proper counseling and education to
maximize test acceptance rates in order to identify
as many infected pregnant women as possible.
The fact that the subjects in the post-intervention
group were less likely to have given no reason for
refusal implies that the educational intervention
resulted in improved counseling of pregnant
women by care providers.
Prospective studies are ideal for decreasing
selection bias and confounding variables, but there
is the potential for cross-over effect. One strength
of this study was its historical cohort nature, in
that there was no possibility for the control group
to have been affected by the intervention.
Another strength lies in the fact that the pre-
and post-intervention provider groups consisted
of the same small number of providers.
By virtue of being a retrospective study, there
are inherent limitations. Results were subject to
bias related to sampling errors. Although the
demographics of the client groups were some-
what different, the results were signiﬁcant after
Table 3 Historical risk factors for HIV acquisition by group
Risk factor Pre-intervention n (%) Post-intervention n (%) *p Value a 50.05
IVDA 17 (6.0%) 16 (7.9%) 0.42
Sex with 45 partners/year 96 (34%) 44 (22%) 0.004
Sex with a man in jail 63 (22.9%) 44 (22.1%) 0.84
Male partners sex with men 1 (0.37%) 2 (1.0%) 0.39
Blood transfusion 2 (0.71%) 3 (1.46%) 0.41
Travel to endemic area 2 (0.71%) 0 (0%) 0.23
Sex with male IVDA 20 (7.4%) 15 (7.6%) 0.94
Sexual assault 22 (7.8%) 13 (6.3%) 0.55
Sex with HIV+ve male 1 (0.36%) 0 (0%) 0.39
Any STD 61 (21.1%) 53 (25.9%) 0.22
N. gonorrheae 24 (8.3%) 15 (7.3%) 0.69
C. trachomatis 81 (27.9%) 35 (17.1%) 0.005
T. vaginalis 33 (11.4%) 15 (7.3%) 0.13
Herpes simplex 44 (15.2%) 7 (3.4%) 50.001
PID 6 (2.1%) 2 (0.98%) 0.34
*Statistics using Fisher’s exact test for statistical signiﬁcance. IVDA, intravenous drug abuse; STD, sexually transmitted disease, PID, pelvic
inﬂammatory disease.
Table 4 Reason for decline of HIV test: number and percentage of refusals in each group
Reason Pre-intervention Post-intervention *p Value
Recently tested 13 (21.3%) 15 (44.1%) 0.02
Denied risk 5 (8.1%) 3 (8.8%) 0.91
Fear of needles 0 (0%) 1 (2.9%) 0.18
Other 1 (1.6%) 0 (0%) 0.46
No reason given 42 (68.9%) 15 (44.1%) 0.02
*Fisher’s exact test used for comparison of frequencies (a 50.05).
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limitation was the inability to account for secular
trends in test offering and acceptance because of
the historical control group. Unfortunately, the
improved rate of test acceptance of 84% was still
below the national recommended standard of
90%. The reasons for this remain unclear and may
be related to geographical and socioeconomic
factors in the study population.
A third limitation of the study is that it was
performed in a setting that may not allow its
results to be generalizable to other populations.
For example, the rates of screening in a private
ofﬁce or a more basic primary care setting may be
much higher or lower than those reported here
and may not be affected as signiﬁcantly by the
presence of an educational intervention. A larger
trial would be necessary to evaluate the rates of
screening in various settings in order to assess the
effectiveness of such an intervention.
Some countries and states have begun a policy
of opt-out rather than opt-in HIV testing for
prenatal care clients. In the opt-out system, rather
than requiring written informed consent to get a
test performed, it is explained to the woman that
HIV is one of the routine prenatal blood tests. She
can then opt out of testing if she desires. It is
thought that this decreases the stigma associated
with HIV testing and improves compliance. In
Alabama and several sites in Canada, opt-out
testing has greatly improved compliance with
universal testing
16. The group at the University of
Alabama reported results similar to ours with opt-
out testing, citing testing rates that increased from
75% to 88%
17. Pennsylvania currently has opt-in
testing and has mandatory non-anonymous state
reporting for clients who test positive for HIV.
There are, however, state-designated anonymous
testing sites. Our Ambulatory Care Clinic is not
one of the anonymous testing sites.
The population studied was at relatively high
risk of HIV infection, in view of the prevalence of
other sexually transmitted infections (Table 3). If a
signiﬁcant proportion of a high-risk population
knew this, testing might be more willingly
accepted than in a low-risk population. Because
we found no subjects to be infected with HIV, we
doubt that there was signiﬁcant bias in the rates of
acceptance,ascomparedwithageneralpopulation.
Mother-to-child transmission of HIV-1 re-
mains at astronomic proportions worldwide. In
the USA, because of superior access to care and
technology, efforts have been made to minimize
transmission in a variety of ways. Prenatal
treatment of HIV-positive women with highly
active anti-retroviral therapy has resulted in
minimal transmission rates
18. In order to treat
such women successfully, however, their HIV
status must be known. Universal screening of
pregnant women has been recommended with
varying success rates for the completion of
screening. In order to assure compliance with
treatment, near perfect compliance with screening
is necessary. This study found an improved rate of
test acceptance after training of prenatal care
providers.
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